Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $11.9 million.

  • Kiniksa Pharmaceuticals International's Cash from Financing Activities rose 77.89% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year increase of 154.25%. This contributed to the annual value of $12.3 million for FY2024, which is 720.47% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Cash from Financing Activities stood at $11.9 million, which was up 11.23% from $10.7 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Cash from Financing Activities ranged from a high of $11.9 million in Q3 2025 and a low of -$178,000 during Q2 2024.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Cash from Financing Activities had a median value of $2.1 million in 2024 and averaged $3.6 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Cash from Financing Activities slumped by 212.66% in 2024, and later skyrocketed by 6,110.11% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cash from Financing Activities (Quarterly) stood at $1.2 million in 2021, then fell by 1.82% to $1.2 million in 2022, then slumped by 41.60% to $695,000 in 2023, then skyrocketed by 208.20% to $2.1 million in 2024, then surged by 77.89% to $11.9 million in 2025.
  • Its Cash from Financing Activities was $11.9 million in Q3 2025, compared to $10.7 million in Q2 2025 and $2.8 million in Q1 2025.